Inhibiting C-Reactive Protein for the Treatment of Cardiovascular Disease: Promising Evidence from Rodent Models
Raised blood C-reactive protein (CRP) level is a predictor of cardiovascular events, but whether blood CRP is causal in the disease process is unknown. The latter would best be defined by pharmacological inhibition of the protein in the context of a randomized case-control study. However, no CRP spe...
Saved in:
Main Authors: | Alexander J. Szalai, Mark A. McCrory, Dongqi Xing, Fadi G. Hage, Andrew Miller, Suzanne Oparil, Yiu-Fai Chen, Michelle Mazzone, Richard Early, Scott P. Henry, Thomas A. Zanardi, Mark J. Graham, Rosanne M. Crooke |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2014/353614 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of Antisense Oligonucleotides against C-Reactive Protein on the Development of Atherosclerosis in WHHL Rabbits
by: Qi Yu, et al.
Published: (2014-01-01) -
C-Reactive Protein (CRP) and Autoimmune Disease: Facts and Conjectures
by: Alexander J. Szalai
Published: (2004-01-01) -
Comparison of Inhibitor and Substrate Selectivity between Rodent and Human Vascular Adhesion Protein-1
by: Ryo Kubota, et al.
Published: (2020-01-01) -
C-Reactive Protein and Arteriosclerosis
by: Jan Torzewski, et al.
Published: (2014-01-01) -
Biomarkers in alcohol use disorder - The promise and pitfalls of neuroimaging drug cue reactivity
by: Marlen Pfisterer, et al.
Published: (2025-06-01)